Lummis Asset Management’s Pfizer PFE Stock Holding History

Lummis Asset Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,314	Closed	-$302K	–	228
2026 Q1	$302K	Hold	11,314	–	–	0.18%	53
2025 Q4	$282K	Hold	11,314	–	–	0.17%	52
2025 Q3	$288K	Hold	11,314	–	–	0.19%	53
2025 Q2	$278K	Hold	11,314	–	–	0.18%	54
2025 Q1	$276K	Buy	+11,314	New	+$296K	0.19%	52
2024 Q1	–	Sell	-11,314	Closed	-$326K	–	175
2023 Q4	$326K	Buy	+11,314	New	+$342K	0.25%	50

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Lummis Asset Management's PFE Position: Q2 2026 in Review

Lummis Asset Management sold out of Pfizer (PFE) in Q2 2026, closing a stake of 11,314 shares — an estimated $302K sold.

Lummis Asset Management first reported a position in PFE in Q4 2023 and held it in 6 quarters. The position peaked at $326K in Q4 2023. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Lummis Asset Management reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Lummis Asset Management sold 11,314 Pfizer shares in Q2 2026, an estimated $302K.
Lummis Asset Management first reported a position in Pfizer in Q4 2023 and held it in 6 quarters.
Lummis Asset Management's Pfizer position peaked at $326K in Q4 2023.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Lummis Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.